Abstract:VPS35 deficiency or mutation can lead to dysfunction in autophagic–lysosomal pathways, abnormal protein accumulation, mitochondrial dysfunction, and impaired neuronal transmission, thereby promoting the onset of neurodegenerative diseases. Furthermore, VPS deficiency or mutation can result in defects in dendritic terminal differentiation, reduced neuronal proliferation, and increased inflammatory responses, inhibiting neurogenesis. The inhibition of neurogenesis exacerbates neurodegenerative diseases, which in turn suppress neurogenesis, creating a vicious cycle. A comprehensive understanding of the relationships between VPS35, neurogenesis, and neurodegenerative diseases is beneficial for elucidating the pathogenesis of neurodegenerative diseases. Targeting VPS35 in relation to neurogenesis holds promise for alleviating neurodegenerative diseases. Vacuolar protein sorting 35 (VPS35), a critical component of the retromer complex, plays a pivotal role in the pathogenesis of neurodegenerative diseases (NDs). It is involved in protein transmembrane sorting, facilitating the transport from endosomes to the trans‐Golgi network (TGN) and plasma membrane. Recent investigations have compellingly associated mutations in the VPS35 gene with neurodegenerative disorders such as Parkinson's and Alzheimer's disease. These genetic alterations are implicated in protein misfolding, disrupted autophagic processes, mitochondrial dysregulation, and synaptic impairment. Furthermore, VPS35 exerts a notable impact on neurogenesis by influencing neuronal functionality, protein conveyance, and synaptic performance. Dysregulation or mutation of VPS35 may escalate the progression of neurodegenerative conditions, underscoring its pivotal role in safeguarding neuronal integrity. This review comprehensively discusses the role of VPS35 and its functional impairments in NDs. Furthermore, we provide an overview of the impact of VPS35 on neurogenesis and further explore the intricate relationship between neurogenesis and NDs. These research advancements offer novel perspectives and valuable insights for identifying potential therapeutic targets in the treatment of NDs.

VPS35-deficiency Results in an Impaired AMPA Receptor Trafficking and Decreased Dendritic Spine Maturation

VPS35 Haploinsufficiency Increases Alzheimer’s Disease Neuropathology

Microglial VPS35 Deficiency Impairs Aβ Phagocytosis and Aβ-induced Disease-Associated Microglia, and Enhances Aβ Associated Pathology.

Vps35 Regulates Developing Mouse Hippocampal Neuronal Morphogenesis by Promoting Retrograde Trafficking of Bace1

VPS35 or retromer as a potential target for neurodegenerative disorders: barriers to progress

Exploring the triad: VPS35, neurogenesis, and neurodegenerative diseases

VPS35 and retromer dysfunction in Parkinson's disease

Vps35 Regulates Cell Surface Recycling and Signaling of Dopamine Receptor D1

Impaired neurogenesis in the hippocampus of an adult VPS35 mutant mouse model of Parkinson's disease through interaction with APP

Expression of Low Level of VPS35-mCherry Fusion Protein Diminishes Vps35 Depletion Induced Neuron Terminal Differentiation Deficits and Neurodegenerative Pathology, and Prevents Neonatal Death

VPS35 Interacts with Dopamine Transportor and Disrupts Dopamine Transporter Recycling Pathway

Mutant D620N and VPS35 induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway

Enhancing Retromer Complex Stability Ameliorates Synaptic Dysfunction in a Mouse Model of Alzheimer's Disease

Mutant VPS35-D620N Induces Motor Dysfunction and Impairs DAT-mediated Dopamine Recycling Pathway.

Mitophagy coordination with retrograde transport ensures the integrity of synaptic mitochondria

RPS23RG1 is Required for Synaptic Integrity and Rescues Alzheimer's Disease-Associated Cognitive Deficits.

Vps35-deficiency Impairs SLC4A11 Trafficking and Promotes Corneal Dystrophy.

Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment

Parkinson's disease–associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes

TRPV1 activation alleviates cognitive and synaptic plasticity impairments through inhibiting AMPAR endocytosis in APP23/PS45 mouse model of Alzheimer’s disease

Retromer pathways can regulate AD‐associated neuronal and microglial phenotypes